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Background: Medication adherence is associated with improved health outcomes in multiple
chronic diseases. Information is needed on the effectiveness of specific adherence interventions.
This study’s objectives were to quantify effects of a targeted mailing intervention on adherence
among older adults at risk for nonadherence, and to examine associations of individual and plan
characteristics with adherence.
Materials and methods: Among adults enrolled in a Medicare Advantage Plan with prescription drug coverage from May 2014 to June 2015, those identified as eligible for the mailing
intervention had a late refill for oral antidiabetic medication, statin, angiotensin-converting
enzyme inhibitor, or angiotensin receptor blocker medication and were previously unreachable
by telephone. Pharmacy claims data were analyzed with the outcome of 6-month proportion
of days covered (PDC) before and after the mailing. The t-test and chi-square analyses were
used to evaluate univariate associations. Multivariable linear and logistic regression models
were conducted to assess relative covariate effects. A sub-analysis of those with at least one
medication fill post-mailing was also performed.
Results: A total of 460 non-adherent individuals aged 70±10.5 years, with 50.2% female and
66.7% white individuals, were included. Of those who were mailed a letter, 24.1% became
adherent to the specified maintenance medication. Those who received 30-day supplies were
more than twice as likely to become adherent after the mailed letter than those who received
30-day supplies or less (P0.05). Baseline higher PDC was also associated with greater
adherence post-mailing (P0.01). A total of 284 (61.7%) individuals filled their medication
at least once after the mailed letter; of those, 39.1% became adherent (mean [SD] change in
PDC =0.15 [±0.28]).
Conclusion: Our findings suggest that a single mailed letter improved medication adherence
by 24.1% in adults with chronic conditions. As a health plan seeking to improve its customers’
well-being and outcomes, Cigna continues to utilize targeted mail interventions to improve
medication adherence.
Keywords: patient compliance, chronic disease, managed care programs, Medicare, Medicare
Part D, Medicare Part C, mail distributions, population health, program evaluation
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Medication adherence has been associated with improved health outcomes in multiple
chronic disease states, including reduced health care utilization and mortality.1–3 Despite
the increased medication costs incurred by adherence, larger savings are realized
through decreased hospital inpatient and emergency department use;4 all-cause medical
costs have been shown to be lower in adherent patients with diabetes, hypertension,
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and hypercholesterolemia.5 Improving medication adherence
to diabetes medication(s) alone could provide a $4.7 billion
annual cost savings.6 The positive effects and importance of
medication adherence are especially emphasized in populations of older adults.
Medicare is the federally-funded United States insurance
program for adults aged 65 years. The Centers for Medicare and Medicaid Services (CMS) incorporates medication
adherence into their Star Ratings.7 These ratings are used
to standardize and compare prevention, satisfaction, and
treatment metrics in order to evaluate and compare health
plan performance nationally (http://healthinsuranceratings.
ncqa.org). Adherence measures that comprise the ratings
include oral antidiabetic medication(s), statin medication,
and angiotensin-converting enzyme inhibitor (ACEI) or
angiotensin receptor blocker (ARB) medication. While the
importance of medication adherence has been increasingly
promoted, recent studies show that medication nonadherence
remains a significant problem and can be as high as 49.1%
in those with chronic conditions.8
In their 2018 study, Easthall et al identified patientlevel barriers to adherence in prevention of cardiovascular
disease and mapped these factors to a conceptual framework designed to create tailored behavioral change.9 Health
plans with an interest in prevention have taken on the role
of partnering with individuals to promote healthy behaviors through behavioral health benefits like telephonic
coaching, and helping to better manage disease through
pharmacy benefits management programs. In-person
patient counseling has been shown to increase adherence,
lower blood hemoglobin A1c levels in patients with diabetes, and lower low-density lipoprotein cholesterol in
coronary artery disease patients.10,11 One literature review
concluded that while pharmacy interventions can improve
medication adherence, when the intervention stops, so
do the effects on adherence.12 Health plans are well positioned to influence medication adherence, and to manage
prevention and treatment at the system, provider, and
individual levels.
Identifying system-level modifiable factors associated with medication adherence may allow more effective
interventions to be developed in the future. In a US veteran
population, Watanabe et al observed that new users of statin
without a copayment were more adherent than their counterparts with a copayment.13 Those utilizing home delivery
have been shown to have higher adherence rates than those
utilizing retail pharmacies.14 Managed care organizations,
such as Medicare Advantage, primarily utilize telephonic
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and mail interventions to reach their participants. While some
studies have shown that pharmacy telephonic interventions
have greater improvement in adherence than mail interventions,15,16 a randomized controlled trial found no difference
in adherence to osteoporosis medication when comparing a
telephone-based counseling intervention to a control group
in a Medicare population.17 While mailed letters to physicians along with plan members have been shown to increase
medication adherence,18,19 the intervention of letters mailed
only to plan members has not been assessed. It is clear from
past research that to be effective, such programs should not
rely on one mode of communication (eg, phone-only), and
take a “multimodal” contact approach consisting of more
than one means of outreach (eg, e-mail, mail, and phone) to
improve adherence.20
The goal of this study was to quantify the impact on adherence of mailed letters, among a targeted Medicare Advantage
population at risk for nonadherence and unreachable by
phone. Eligible individuals were identified if they were late
to refill their chronic disease management medications. If
they could not be contacted by telephone, a letter specifying the medication that needed to be refilled was mailed to
the address on file. Evaluating the effectiveness of these
mailed letters on improving the proportion of days covered
(PDC) rate and examining both modifiable and static factors
influencing adherence may allow future interventions to be
more effective in targeting at-risk individuals and improving
overall PDC rates in the Medicare population.

Materials and methods
Study design and selection
The study protocol was reviewed and approved by the
University of Houston Institutional Review Board. A retrospective pre–post study was performed on adults enrolled in
a Medicare Advantage Plan with prescription drug coverage
from May 2014 to June 2015. Individuals must have been
continuously enrolled in the health plan throughout the
measurement period, and eligible to receive an adherencefocused letter via mail within November and December
2014 as part of the Medicare Advantage Plan’s adherence
program. Mailing eligibility criteria included having received
(per pharmacy claims) a prescription for a statin medication,
ACEI or ARB medication, or oral antidiabetic medication in
the year 2014, and having been late picking up their refill.
The letters were mailed if the individual did not answer a
phone call from a pharmacy representative within three phone
call attempts or was otherwise unreachable by phone. The
letters contained individually tailored information including
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name, medication name (or names compiled through mail
merge if they were behind on more than one medication),
last date medication was filled, name and phone number of
the pharmacy from which they last picked up the medication,
a general statement of the importance of taking prescribed
medication and adhering to prescriber recommendations, and
the health plan regional Medical Director name and contact
number for questions.
An initial total of 541 individuals were eligible for prescreening, in which phase letters were not sent if there had
not been at least two fills of the specified medication in the
year 2014 (n=14), or if the individual was adherent to the
specified medication, defined as PDC 0.8, before the letter
was sent (n=67). In total, 460 letters were sent. Selection
criteria are illustrated in Figure 1.

Study variables and outcome measures
Letters were written in the preferred language designated
by the recipient (English or Spanish). Demographic characteristics were included to ensure representativeness and
generalizability of the findings, account for possible confounding, and assist targeting future interventions; these
factors included age, gender, self-reported ethnicity, and low
income subsidy eligibility, which were obtained from the
customer benefits database. Region was classified as West
Texas (areas Northwest, Southwest, and West of the Houston
metropolitan area), East Texas (areas Northeast, Southeast,
East, and including the Houston metropolitan area), or Not
in Texas, based on residence zip code.

Medication characteristics were obtained from the pharmacy benefits management database. The specified medications in the letters were identified via National Drug Code
numbers. Medication category was denoted as statin, ACEI
or ARB, or oral antidiabetic. Brand or generic was denoted
based on the medication name specified in the sent letter.
Day supply, copay, the pharmacy at which the medication
was filled at, and the fill history of the specified medication
was also obtained. The day supply, copay, and pharmacy
information were identified based on a claim for the specified
medication’s fill just prior to the letter being sent. Copay was
defined as the out-of-pocket expense to the customer for the
medication. Pharmacy type was classified as either retail or
mail-order pharmacy.
Outcomes were also obtained and calculated from the
pharmacy benefits management database. PDC was chosen
as the outcome measure for its documented correlation with
other adherence measures.21,22 A threshold of PDC 0.8 is
commonly used to denote dichotomous adherence in extant
studies,1,23–25 and is used in the Medicare Star Ratings benchmarking program to compare health plans and providers.
Initial PDC rate was calculated from pharmacy claims data
6 months prior to the date the letter was sent. Final PDC was
calculated from pharmacy claims data 6 months after the date
the letter was sent. Change in PDC was calculated as the difference between initial and final PDC. The primary outcome
of adherence was defined as a final PDC 0.8. Individuals
were considered to have filled their medication after the
letter was sent if there was at least one pharmacy claim for

Medicare Advantage program participants with prescription drug
coverage from May 2014 to June 2015 who had received a
prescription for a statin medication, ACEI or ARB medication, or oral
antidiabetic medication in the year 2014, and were late picking up
their refill (N=514)

Excluded
• Less than two fills of specified
medication in previous year
(n=14, 3%)
• Proportion of days covered >0.8
(n=67, 13%)

Included
Analytic sample

Mailing eligible (n=460, 89%)

Sub-analysis

At least one fill of medication after
letter was sent (n=284, 62%)

Figure 1 Customer selection flowchart.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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the specified medication in the 6 months after the letter was
sent. Days before the next fill of the specified medication
were calculated based on the date the letter was sent and the
pharmacy claims data.
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Statistical analysis
Chi-square proportion tests and Student’s t-tests were
conducted to describe univariate relationships between
adherence and individual and medication characteristics.
A Fisher’s exact test was used to compare proportions
of the population with PDC 0.8 before and after the
mailing. A sub-analysis of 284 individuals who filled the
specified medication at least once after the letter was sent
was performed to analyze those who did not likely discontinue the medication class or switch to another medication
within-class.
Two regression models were built to evaluate patient
characteristics associated with better adherence among
the patients who received the letters, as adherence is
best measured using more than one outcome variable.
A multiple linear regression analysis was conducted with
an outcome of change in PDC (Table 1). Independent
variables included medication type and individual characteristics. A multiple logistic regression analysis with the
same independent variables was also carried out with an
adherence outcome defined as a final PDC 0.8 (Table 2).
The days’ supply variable was dichotomous (30 or fewer
days’ supply vs 30 days’ supply) for both the linear and
logistic regression models. Multiple regression was also
used to analyze the subset of 284 individuals who filled
the specified medication at least once after the mailed letter
was analyzed (Tables S1 and S2). All statistical analyses
were performed utilizing SAS Version 9.3 (SAS Institute
Inc., Cary, NC, USA).
Table 1 Linear regression analysis of change in 6-month PDC
before vs after the mailed letter
Language of letter
Age
Gender
Ethnicity
Region
Low income subsidy eligibility
Medication category
Generic vs brand
Day supply
Copay
Pharmacy type

Beta (standard error)

P-value

−0.050 (0.048)
−0.004 (0.002)
−0.044 (0.037)
−0.019 (0.023)
0.027 (0.029)
0.024 (0.040)
0.010 (0.026)
0.033 (0.086)
0.123 (0.039)
−0.002 (0.002)
0.020 (0.121)

0.299
0.041
0.238
0.410
0.342
0.553
0.693
0.701
0.002
0.180
0.872

Abbreviation: PDC, proportion of days covered.
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Table 2 Logistic regression analysis of adherence defined as
6-month PDC of at least 80% after the mailed letter
Language of letter
English
Spanish
Age
Age, years
Gender
Female
Male
Ethnicity
White
Hispanic
African-American
Asian
Region of Texas
Out of Texas
West
East
Low income subsidy eligibility
No
Yes
Medication category
Statin
ACEI/ARB
Oral antidiabetic
Generic vs brand
Generic
Brand
Day supply
30 days or less
30 days
Copay
Copay, $
Pharmacy type
Retail
Mail order
Initial PDC
PDC

OR (95% CI)

P-value

Reference
0.739 (0.383–1.426)

Reference
0.368

0.994 (0.972–1.016)

0.594

Reference
0.968 (0.615–1.524)

Reference
0.888

Reference
0.673 (0.323–1.402)
1.008 (0.538–1.888)
1.049 (0.185–5.937)

Reference
0.291
0.981
0.957

Reference
1.359 (0.338–5.471)
1.563 (0.401–6.091)

Reference
0.666
0.520

Reference
1.189 (0.725–1.951)

Reference
0.492

Reference
0.649 (0.396–1.061)
0.777 (0.406–1.489)

Reference
0.085
0.447

Reference
0.773 (0.262–2.281)

Reference
0.641

Reference
2.198 (1.307–3.696)

Reference
0.003

0.994 (0.973–1.016)

0.587

Reference
1.028 (0.254–4.159)

Reference
0.969

39.283 (2.764–558.363)

0.007

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; PDC, proportion of days covered.

Results
Table 3 shows that while 40% (140/349) of the non-adherent
participants had medication supply of 30 days or fewer, only
30 (27%) of the 111 adherent participants had supply of
30 days or less. Initial PDC was also higher among adherent vs
non-adherent participants (mean =0.54 vs 0.51, P=0.013).
Of the 460 non-adherent participants who were mailed
letters, 111 (24.1%) became adherent after the mailed letter
(Fisher’s exact test 0.001) and the mean (± SD) change
in PDC was −0.10 (±0.40). The mean (SD) age of the participants was 69.98 (±10.48) years, with 50.2% female and
66.7% self-reported as white race individuals. Univariate
chi-square and Student’s t-test comparisons among categories

Patient Preference and Adherence 2019:13

Dovepress

Targeted mailing interventions to improve medication adherence

Patient Preference and Adherence downloaded from https://www.dovepress.com/ by 152.38.169.250 on 11-Oct-2019
For personal use only.

Table 3 Baseline Medicare Advantage Plan participant and medication characteristicsa

Language of letter
English
Spanish
Age
Age, years
Gender
Female
Male
Ethnicity
White
Hispanic
African-American
Asian
Region
Out of Texas
West Texas
East Texas
Low Income subsidy eligibility
No
Yes
Medication category
Statin
ACEI/ARB
Oral antidiabetic
Generic vs brand
Generic
Brand
Day supply
30 days or less
30 days
Copay
Copay, $
Pharmacy type
Retail
Mail order
Initial PDC
PDC

n (%)

Not adherent
at final, n (%)

Adherent at
final, n (%)

362 (78.7)
98 (21.3)

270 (74.6)
79 (80.6)

92 (25.4)
19 (19.4)

70.0±10.5

70.1±10.7

69.6±9.9

231 (50.2)
229 (49.8)

174 (75.3)
175 (76.4)

57 (24.7)
54 (23.6)

307 (66.7)
66 (14.4)
80 (17.4)
7 (1.5)

232 (75.6)
54 (81.8)
58 (72.5)
5 (71.4)

75 (24.4)
12 (18.2)
22 (27.5)
2 (28.6)

16 (3.5)
221 (48.1)
223 (48.5)

13 (81.3)
171 (77.4)
165 (74.0)

3 (18.8)
50 (22.6)
58 (26.0)

222 (48.3)
238 (51.7)

171 (77.0)
178 (74.8)

51 (23.0)
60 (25.2)

196 (42.6)
189 (41.1)
75 (16.3)

141 (71.9)
150 (79.4)
58 (77.3)

55 (28.1)
39 (20.6)
17 (22.7)

431 (93.7)
29 (6.3)

326 (75.6)
23 (79.3)

105 (24.4)
6 (20.7)

170 (37.0)
290 (63.0)

140 (82.4)
209 (72.1)

30 (17.7)
81 (27.9)

P-value
0.216b

0.676c
0.784b

0.602b

0.576b

0.575b

0.223b

0.655b

0.013b

0.782c
4.36±12.64

4.45±13.41

4.07±9.89

449 (97.6)
11 (2.4)

341 (76.0)
8 (72.7)

108 (24.1)
3 (27.3)

0.51±0.11

0.51±0.12

0.54±0.09

0.805b

0.013c

Notes: aValues represent mean ± SD for age, copay, and initial PDC. bChi-squared test. ct-Test.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; PDC, proportion of days covered.

for the outcome of adherence are reported in Table 3. The
medications specified in the letter were primarily for generics
(93.7%) and were comprised of statins (42.6%), ACEIs or
ARBs (41.1%), and oral antidiabetic medications (16.3%).
Those who filled more than 30 days of medication at a time
were more likely to become adherent after the mailed letter
than those who filled a 30-day supply or less (chi-square
P=0.013). Also, the mean (SD) initial PDC was 0.51 (±0.11)
and there was a significant difference in initial PDC between
those who became adherent after the mailed letter and those
who did not (Student’s t-test, P=0.013).
A total of 284 (61.7%) participants filled the specified
medication at least once after the mailed letter. Adherence

Patient Preference and Adherence 2019:13

data for this subset along with the overall cohort are reported
in Table 4. Of this subset, 39.1% became adherent after the
letter was mailed and the mean (SD) change in PDC was
0.15 (±0.28). There was a mean (SD) of 39.01 (±42.58) days
before the next fill after the date the letter was mailed.
The multiple linear regression results for the outcome of
change in PDC are presented in Table 1 for the whole cohort.
Days’ supply was found to be significantly associated with
change in PDC (β standard error [SE] =0.12 (0.04), P=0.002).
Also, age was significantly associated with a small decrease
in PDC (β [SE] =−0.004 [0.002], P=0.041). Medication
category was not significantly associated with change in
PDC in this model.
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Table 4 PDC rates and adherence dataa
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Total sample
Total letters (n)
Initial PDC (mean ± SD)
Final PDC (mean ± SD)
Change in PDC (mean ± SD)
Adherent at final, n (%)
No
Yes
Filled after letter, % (n)
No
Yes

Participants with one or more medication fill after the letter
was sent
460
0.51±0.11
0.41±0.39
−0.10±0.40
349 (75.9)
111 (24.1)
38.5 (176)
61.7 (284)

284
0.52±0.11
0.67±0.28
0.15±0.28
60.9 (173)
39.1 (111)
39.01
42.58

Note: aValues represent mean ± SD for initial PDC, final PDC, change in PDC, and days before next fill.
Abbreviation: PDC, proportion of days covered.

The multiple logistic regression results for the outcome
of adherence after the mailed letter with a C-statistic of
0.63 are displayed in Table 2 for the entire cohort. Those
who filled a 30-day supply of medication at a time had
increased adherence after the mailed letter, compared to
those who filled less than a 30-day supply (OR =2.2; 95%
CI =1.3–3.7; P=0.003). Initial PDC was also significantly
associated with becoming adherent after the mailed letter
(OR =39.3; 95% CI =2.8–558.4; P=0.007). Neither age nor
medication type (statin medications vs ACEIs or ARBs) was
significantly associated with adherence improvements in the
multivariable model.
Tables S1 and S2 report multiple regression analyses
of the subset who filled the specified medication at least
once after the mailed letter. Initial PDC was not assessed
in these analyses. Days’ supply was found to be associated positively with change in PDC within this model
(β [SE] =0.14 [0.034]; P0.001). Also, in the subset, Texas
vs out-of-state geographic region was associated with change
in PDC (β [SE] =0.045 [0.022]; P=0.045). The multiple
logistic regression results for the outcome of adherence had
a C-statistic of 0.745. Days’ supply 30 days at baseline was
associated with greater adherence compared to those with a
30-day supply or less (OR =2.743; 95% CI =1.514–4.970;
P=0.001). There was a significant difference in initial PDC
between those who became adherent after the mailed letter
and those who did not (OR =39.283; 95% CI =2.764–558.363;
P=0.007). Region and generic medications were not identified
as significant predictors of adherence in this model.

Discussion
The present study demonstrated a 24.1% increase in adherence following a pharmacy intervention of a single mailed
letter sent to a population of older individuals previously
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Final PDC (mean ± SD)
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Adherent at final, n (%)
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Days before next fill
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non-adherent to statins, ACEI/ARBs, or oral antidiabetic
medications, and who were previously unreachable by
telephone.
While our data did not corroborate past research suggesting higher adherence to ACEI compared to other medication
classes,26,27 the overall increase of 24.1% among these specific
medications targeting chronic disease prevention (statins,
ACE inhibitors/ARBs, and oral antidiabetic medications)
was associated with PDC at baseline, and with days’ supply.
The mailing strategy and medications studied appear welltargeted for effectiveness in chronic diseases given past
research showing that mailed letters increased adherence to
antidepressant medication by only 2% compared to controls.18
Our data also corroborate past research on the added value of
multiple modes of contact at the patient, provider, and system
levels; Jing et al describe that mailed letters to physicians
can lower nonadherence rates from 35.6% to 30.8%, with
a decrease to 27.7% when patients are also mailed letters.19
Managed care organizations should consider a strategy of
tailored mailings to try to reach all of their non-adherent
customers in an effort to improve patient health outcomes
and improve plan quality ratings.
Individuals who filled more than 30 days of medication at a time were more likely to become adherent after
the mailed letter than those who filled a 30-day supply or
less. Also, higher initial PDC was a significant predictor of
becoming adherent after the mailed letter. These findings are
consistent with past studies’ findings of higher adherence
rates with 90- vs 30-day supply.28,29 There is evidence that
automatic refill programs can be properly managed in chronic
disease maintenance to avoid oversupply with both 30- and
90-day prescriptions, and that such programs are suitable
for patients who have memory or transportation barriers to
refilling medications at regular pharmacies.30 To improve
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medication adherence, Medicare Advantage Plans should
encourage their customers and prescribers to use 90- rather
than 30-day supplies of chronic medications.
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Limitations and strengths
More than one-third of those who received a mailed letter
(38.5%) did not fill the specified medication within 6 months.
It is a limitation of the present study that the claims data did
not allow exclusions due to provider-instructed medication
discontinuation or switching. Determining such cases and
excluding them before mailing letters would reduce the
denominator and improve effectiveness as measured by
PDC, also helping target the intervention further to applicable
prescribing patterns.
Valid and reliable adherence measurement using claims
data has always posed a challenge in research. Use of PDC
as an outcome measure carries certain limitations, including
the possibility that a prescription could be filled according
to schedule but not taken as prescribed. Medication event
monitoring systems such as pill bottle caps or daily logs
were designed to overcome this challenge, but a potential
measurement bias where medications were being filled and
“stockpiled” rather than taken would apply to customers
using mail-order pharmacies,14 only 11 individuals (less
than 2% of the analytic sample in the present study) used
home delivery or mail-order pharmacies. While our data
demonstrated a higher adherence rate in those using home
delivery or mail-order pharmacies (27% adherent after the
letter) vs those using retail pharmacies (24% adherent after
the letter), these counts were too small to evaluate statistical
significance.
Age was significantly associated with the outcome of
change in continuous PDC in the linear regression, but not
for dichotomous PDC in the logistic regression. In this study,
individuals previously non-adherent to statin medications
showed greater responsiveness to the mailing than those
previously non-adherent to ACEIs or ARBs. Conversely,
one study demonstrated oral antidiabetic medication as
being a significant predictor of adherence compared to ARBs
and statins.27 Future research should continue to evaluate
the relative effects of disease-specific factors among these
chronic conditions.
There was no statistically significant medication adherence differences according to measured categories of ethnicity, copay, or pharmacy type, despite having previous
literature support the association between these characteristics and medication adherence. While minorities have been
shown to have lower adherence in some studies,31,32 in this
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analysis there was no detectable difference by race. Our data
did not corroborate previous research from 2014 concluding an effect of copayment on adherence,13 but this could be
due to the fact that the previous study was conducted in an
exclusively veteran population.
One assumption in the present study was that each
individual who was mailed a letter also received and read
the letter. However, the address listed in the organization’s
system may have been incorrect, the letter may never have
been opened, or there could have been language or literacy
barriers. Also, this study analyzed only pharmacy prescription claims viewed by the Medicare Advantage Plan. If a
person had multiple insurance providers or paid cash for some
of their prescriptions, this would not have been captured in
the analysis.
This study also assumed that each individual being
prescribed these medications should be taking them every
day, while some indications may utilize alternative dosing. However, this inaccuracy would be consistent across
multiple time points and is also present in the CMS Part
D Stars Ratings (the national federal agency plan quality
rating system). To address the possibility that individuals
may have discontinued or switched medication throughout
the year, a sub-analysis of those who filled the medication
at least once after the mailed letter was performed. As
shown in Table 4 as well as Tables S1 and S2, the results
were robust to varying this assumption. Another limitation
of this study was its pre–post design, which led to limited
causal inference.33 However, claims data investigations that
require continuous enrollment to be included in the analytic
sample are important in planning and allocating resources
for improving quality of care and designing prospective
randomized studies.
In quantifying improvements in adherence among Medicare Advantage participants using PDC and pharmacy claims
data, this study maximized health plan data resources and
population health analytics to identify a mailing intervention
for further use and investigation.

Conclusion
A single mailed letter significantly improved medication
adherence by 24.1% in a non-adherent population that could
not be reached previously by telephone. To our knowledge,
this is the first study to analyze the targeted intervention concomitantly with multiple individual-, plan-, and system-level
characteristics associated with improved medication adherence in chronic diseases. Future studies should incorporate
a control group, and track associated health outcomes as
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a measure of intervention effectiveness. As a health plan
seeking to improve its customers’ well-being and outcomes,
teams within Cigna are continuing to utilize targeted mailing
interventions to help improve medication adherence.
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Supplementary materials
Table S1 Sub-analysis of letter recipients with medication filled
after letter was sent (n=284)

Table S2 Sub-analysis of letter recipients with medication filled
after letter was sent (n=284)

Linear regression analysis of change in PDC – change in
6-month PDC from before the mailed letter to after the
mailed letter

Logistic regression analysis of adherence as measured by
6-month PDC of at least 80% after the mailed letter

Language of letter
Age
Gender
Ethnicity
Region: Texas vs out of state
Low income subsidy eligibility
Medication category
Generic vs brand
Day supply
Copay
Pharmacy type

Beta (standard error)

P-value

−0.009 (0.044)
−0.001 (0.002)
−0.001 (0.033)
−0.030 (0.021)
0.045 (0.022)
0.043 (0.037)
−0.007 (0.022)
−0.060 (0.077)
0.144 (0.034)
−0.001 (0.003)
0.032 (0.104)

0.834
0.478
0.980
0.153
0.045
0.251
0.755
0.436
0.001
0.802
0.762

Abbreviation: PDC, proportion of days covered.

Language of letter
English
Spanish
Age
Age, years
Gender
Female
Male
Ethnicity
White
Hispanic
African-American
Asian
Region of Texas
Out of Texas
West
East
Low income subsidy eligibility
No
Yes
Medication category
Statin
ACEI/ARB
Oral antidiabetic
Generic vs brand
Generic
Brand
Day supply
30 days or less
30 days
Copay
Copay, $
Pharmacy type
Retail
Mail order

OR (95% CI)

P-value

Reference
0.948 (0.418–2.148)

Reference
0.898

1.001 (0.975–1.028)

0.939

Reference
1.045 (0.604–1.811)

Reference
0.874

Reference
0.642 (0.266–1.553)
0.743 (0.344–1.603)
–

Reference
0.326
0.449
0.987

Reference
0.524 (0.088–3.142)
0.912 (0.181–4.603)

Reference
0.480
0.911

Reference
1.667 (0.888–3.130)

Reference
0.112

Reference
0.777 (0.425–1.422)
0.743 (0.341–1.619)

Reference
0.413
0.455

Reference
0.305 (0.081–1.147)

Reference
0.079

Reference
2.743 (1.514–4.970)

Reference
0.001

1.021 (0.981–1.064)

0.303

Reference
0.845 (0.154–4.649)

Reference
0.847

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; PDC, proportion of days covered.
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